Insight Molecular Diagnostics Inc. (IMDX)

US — Healthcare Sector
Peers: BDSX  SERA  PRPO  APDN  LCTX  VTVT  CLSD  SLDB  XBIO 

Automate Your Wheel Strategy on IMDX

With Tiblio's Option Bot, you can configure your own wheel strategy including IMDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IMDX
  • Rev/Share 0.1496
  • Book/Share 0.3977
  • PB 6.6259
  • Debt/Equity 0.3404
  • CurrentRatio 3.745
  • ROIC -1.1247

 

  • MktCap 75359156.0
  • FreeCF/Share -0.8925
  • PFCF -3.2863
  • PE -1.1632
  • Debt/Assets 0.0576
  • DivYield 0
  • ROE -7.6691

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
IMDX, TXG, VEEV
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive

AI momentum and rising demand for digital care put Zacks Medical Info Systems industry stocks like VEEV, TXG and IMDX in focus despite new tariff headwinds.

Read More
image for news 3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk

About Insight Molecular Diagnostics Inc. (IMDX)

  • IPO Date 2015-12-30
  • Website https://imdxinc.com
  • Industry Biotechnology
  • CEO Joshua Riggs
  • Employees 46
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.